This content surveys the class-based logic underlying modern oncology drug regulatory approval: therapies are increasingly designed around a specific molecular mechanism or target (e.g., JAK2 inhibition, kinase-fusion inhibition, antiandrogen receptor blockade, antibody-drug conjugates, selective nuclear export inhibition, PI3K-pathway inhibition) and approved either broadly for a histologic disease category or narrowly for a molecularly defined patient subset identified via biomarker or genomic testing. The organizing theoretical principle is precision/targeted oncology therapeutics, in which mechanism of action, the presence of a defined molecular alteration, and comparative trial endpoints (response rate, progression-free survival, overall survival, and toxicity profile) jointly determine a drug's approved indication and its place relative to existing agents in the same therapeutic class; this situates the concept within hematology-oncology pharmacology and clinical drug development.
This content surveys the class-based logic underlying modern oncology drug regulatory approval: therapies are increasingly designed around a specific molecular mechanism or target (e.g., JAK2 inhibit…